<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="672">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 14, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02359500</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 14-2008</org_study_id>
    <nct_id>NCT02359500</nct_id>
  </id_info>
  <brief_title>68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)</brief_title>
  <official_title>Safety and Efficacy Study of 68Ga-Dotatoc Positron Emission Tomography for Diagnosis for Staging, Restaging and Assessment of Response to Treatment in Somatostatin Receptor-Positive Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lale Kostakoglu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mount Sinai School of Medicine</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to demonstrate the safety and efficacy of [68Ga]-DOTA-tyr3-Octreotide
      ([68Ga]-DOTATOC) as an accurate imaging technique for diagnosis, staging, and monitoring of
      response to treatment in patients with Somatostatin receptor expressing tumors who undergo
      imaging with a clinical indication. The investigators will conduct a study for 68Ga-DOTATOC
      as a diagnostic PET/CT imaging agent for the detection of NETs, mainly carcinoid tumors.
      68Ga-DOTATOC will be used in diagnostic assessment of patients with known or suspected NETs
      for whom there is an appropriate standard clinical indication for 68Ga-DOTATOC PET/CT either
      at staging or during follow up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale and overall study design This study is planned to demonstrate the safety and
      efficacy of [68Ga]-DOTA-tyr3-Octreotide ([68Ga]-DOTATOC) as an accurate imaging technique
      for diagnosis, staging, and monitoring of response to treatment in patients with
      Somatostatin receptor expressing tumors who undergo imaging with a clinical indication.

      Neuroendocrine tumors (NET) are rare neoplasms of neuroendocrine origin. Neuroendocrine
      tumors are solid malignant tumors that arise from dispersed neuroendocrine cells found
      throughout the body. They are well known for their heterogeneity which makes it difficult to
      obtain uniform clinical data and establish universal guidelines for the diagnosis and
      treatment of NETs. NETs are characterized by overexpression of somatostatin receptors, which
      can be visualized and targeted by radiolabeled somatostatin analogues.
      111In-diethylenetriaminepentaacetic acid-octreotide scintigraphy (111In-Octreotide) with
      single photon emission tomography (SPECT) is currently the standard imaging modality for
      evaluating patients with NETs. 111In Octreotide is the only FDA approved radiopharmaceutical
      available on the market for assessing the extent of involvement by NETs at both staging and
      follow up periods. However, the sensitivity of this imaging modality is lower compared to
      the positron emission tomography (PET) radiotracer 68Ga-DOTA0-Tyr3]octreotide
      (68Ga-DOTA-TOC). Based on the improved sensitivity, 68Ga DOTATOC PET leads to significant
      changes in 30% of patients.  Importantly, the radiation exposure of 68Ga-DOTATOC PET is
      lower than that of 111In Octreotide and also the imaging with 68Ga-DOTATOC PET scan yields
      fast read-outs on the same day compared to 24-48 hour read-outs with 111In Octreotide scan.
      These advantages make the 68Ga labeled somatostatin analog more attractive from both the
      patient and management perspectives. The improved resolution and quantitation of uptake
      obtained with Ga-68 DOTATOC PET should provide a more accurate assessment of somatostatin
      receptor density, which will lead to a more accurate prediction of treatment response to
      somatostatin analogues.

      While the investment costs for the scanner, the radiochemistry equipment are higher for
      68Ga-DOTATOC PET/CT compared with 111In-DTPA-octreotide scintigraphy and SPECT, with the
      provision of this imaging molecule by an established commercial radiopharmaceutical company
      that in with compliance to FDA 21 CFR Part 212 IBA Molecular Inc, NJ, USA, this will not
      pose a limitation for the Mount Sinai Medical Center. In this setting, 68Ga-DOTATOC PET/CT
      production and personnel costs will be borne by the commercial entity, however, Mount Sinai
      Medical Center will purchase the 68Ga-DOTATOC based on a per patient schedule. Since this
      imaging modality does not have a quote for reimbursement by the insurance carriers, the
      imaging cost is considered a potential burden on the patient until it is approved by the
      U.S. Food and Drug Administration (FDA). There is significant amount of European based
      clinical data (&gt;1000 patients) to prove the safety and efficacy of this imaging agent,
      therefore, a phase II or III clinical trial in the US is redundant and will only delay the
      approval of this imaging probe. Recently, Ga-68 DOTATOC has been designated as an orphan
      drug by the FDA for the management of NET. This designation will probably lead to faster
      approval of the agent, which would greatly benefit NET patients in the US. Currently, there
      are only several small U.S.-based clinical trials for Ga-68 labeled NET PET agents available
      for patients; otherwise they must travel out of the country if the scan is required to
      manage their disease.

      The investigators, therefore, aim to provide this superior imaging technique to NET patients
      for better disease management by the referring physicians, however, this objective cannot be
      attained unless at least a partial funding mechanism exists to make it affordable by the
      patients until the approval of this superior imaging probe. In this regard, the
      investigators are aiming at recovering the cost of the radiotracer from the local insurance
      carrier through the cost recovery system.

      Participant Enrollment Participants will be recruited from the Mount Sinai Medical Center.
      Participants who will be approached regarding the study are those individuals who are being
      seen for known or suspected malignancies.

      Patients may remain on their somatostatin therapies throughout the study with no management
      change merely based on the 68Ga -DOTATOC PET/CT imaging findings. The management of these
      patients will be based on the standard of care and any change will be at the discretion of
      the referring physician. All pertinent dosing information must be collected and reported.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Change in size of lesion</measure>
    <time_frame>baseline and 1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in size of lesion at 1 month as compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of new lesions</measure>
    <time_frame>baseline and 1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of new lesions at 1 month as compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of change in treatment</measure>
    <time_frame>baseline and 1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in treatment caused by result of 68Ga-DOTATOC PET/CT at 1 month as compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of previously unknown primary tumor</measure>
    <time_frame>baseline and 1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence of identification of the location of a previously unknown primary tumor at 1 month as compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Carcinoid Tumors</condition>
  <arm_group>
    <arm_group_label>68Ga-DOTATOC PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with known or suspected somatostatin receptor positive neuroendocrine tumors (NETs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>68Ga-DOTATOC PET</intervention_name>
    <description>68Ga-DOTATOC as a diagnostic PET/CT imaging agent for the detection of NETs, mainly carcinoid tumors.</description>
    <arm_group_label>68Ga-DOTATOC PET</arm_group_label>
    <other_name>[68Ga]-DOTA-tyr3-Octreotide</other_name>
    <other_name>[68Ga]-DOTATOC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Known or suspected somatostatin receptor positive NETs (e.g. carcinoid, pancreatic
             neuroendocrine tumors, and pheochromocytoma). Supporting evidence may include MRI,
             CT, biochemical markers, and or pathology report.

          -  Karnofsky performance status of â‰¥50 (or ECOG/WHO equivalent)

          -  Off Sandostatin (octreotide acetate)-long acting release (LAR) &gt; 4 weeks and off
             immediate release (subcutaneous) for at least 12 hrs prior to 68Ga-DOTATOC PET-CT
             imaging

          -  Able to provide informed consent

          -  At least 18 years of age

        Exclusion Criteria:

          -  Pregnancy or breast feeding. A negative serum pregnancy test is required for all
             female subjects with child- bearing potential

          -  Surgical resection, chemotherapy, radiation therapy, or biologic therapy since last
             Octreoscan + CT; continuation of the same dose of Sandostatin-LAR or subcutaneous
             Sandostatin is allowed

          -  Medical condition uncontrolled by treatment making completion of study unlikely

          -  Patients exceeding the weight limitations of the scanner or are not able to enter the
             bore of the PET/CT scanner due to Body Mass Index (BMI)

          -  Inability to complete the needed investigational and standard-of-care imaging
             examinations due to other reasons (e.g. severe claustrophobia)

          -  Any additional medical condition, serious intercurrent illness or other extenuating
             circumstance that, in the opinion of the Investigator, may significantly interfere
             with study performance or interpretation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lale Kostakoglu, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew Drexel</last_name>
    <phone>212-241-0763</phone>
    <email>matthew.drexel@mountsinai.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lena Marra</last_name>
    <phone>212-241-9369</phone>
    <email>lena.marra@mountsinai.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lale Kostakoglu, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 9, 2015</lastchanged_date>
  <firstreceived_date>January 23, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mount Sinai School of Medicine</investigator_affiliation>
    <investigator_full_name>Lale Kostakoglu</investigator_full_name>
    <investigator_title>Chief of Nuclear Medicine and Molecular Imaging</investigator_title>
  </responsible_party>
  <keyword>68Ga- DOTATOC</keyword>
  <keyword>Diagnosis</keyword>
  <keyword>Somatostatin Receptor-Positive Neuroendocrine Tumors</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apudoma</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edotreotide</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
